RxDoctor Payments Data

Anna Stewart, APRN

Adult Health · Paducah, KYNPI 1942535497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.

$1,377in general payments, 2019–2025

Across 66 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$319
  • Vifor Pharma, Inc.$244
  • Bayer$162
  • AstraZeneca$145
  • Akebia Therapeutics Inc$107
  • Ardelyx, Inc.$78
  • plus $321 from 8 others

What the payments were for

  • Food & beverage$1,25991%
  • Education$1179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,377 in reported general payments places this provider in the 70th percentile of 170 adult health providers in Kentucky.

See all adult health providers in Kentucky

Medicare billing

Part B allowed, 2024
$16,345
Medicare patients
57
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate184$508,254
XphozahTenapanor Hcl63$285,323
VelphoroSucroferric Oxyhydroxide51$224,325
Sevelamer Carbonate178$45,305
RenvelaSevelamer Carbonate26$41,768
VeltassaPatiromer Calcium Sorbitex19$13,754
Midodrine Hcl77$10,826
EliquisApixaban12$7,016
Calcium Acetate24$3,039
Bumetanide58$1,914
Ondansetron OdtOndansetron38$856
Nifedipine ErNifedipine31$802
Losartan Potassium70$336
Megestrol Acetate27$311
Clonidine Hcl26$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$107$508,254184 claims
Fresenius USA Marketing, Inc.Velphoro$319$224,32551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 170 adult health providers in Kentucky.

Other adult health in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →